Similar articles

• Rapid hair depigmentation in patient treated with pazopanib.

  Šeparović R, Pavlović M, Silovski T, Tečić Vuger A.Šeparović R, et al.BMJ Case Rep. 2018 Aug 23;2018:bcr2018224209. doi: 10.1136/bcr-2018-224209.BMJ Case Rep. 2018.PMID:30139781Free PMC article.
• Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

  Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium.Bible KC, et al.Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.Lancet Oncol. 2010.PMID:20851682Free PMC article.Clinical Trial.
• Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.

  Koehler VF, Berg E, Adam P, Weber GL, Pfestroff A, Luster M, Kutsch JM, Lapa C, Sandner B, Rayes N, Fuss CT, Kreissl MC, Hoster E, Allelein S, Schott M, Todica A, Fassnacht M, Kroiss M, Spitzweg C.Koehler VF, et al.Thyroid. 2021 Oct;31(10):1531-1541. doi: 10.1089/thy.2021.0091.Thyroid. 2021.PMID:34405734
• Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.

  Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M, Wehland M.Milling RV, et al.Int J Mol Sci. 2018 Oct 20;19(10):3258. doi: 10.3390/ijms19103258.Int J Mol Sci. 2018.PMID:30347815Free PMC article.Review.
• Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.

  Stein J, Milhem M, Vaena D.Stein J, et al.J Oncol Pharm Pract. 2020 Jan;26(1):232-235. doi: 10.1177/1078155219841108. Epub 2019 Apr 8.J Oncol Pharm Pract. 2020.PMID:30961437Review.

Cited by

• Phototoxic Reaction Induced by Pazopanib.

  Udompanich S, Chanprapaph K, Rajatanavin N.Udompanich S, et al.Case Rep Dermatol. 2018 Nov 21;10(3):251-256. doi: 10.1159/000494611. eCollection 2018 Sep-Dec.Case Rep Dermatol. 2018.PMID:30519172Free PMC article.
• Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

  Davidson BA, Secord AA.Davidson BA, et al.Int J Womens Health. 2014 Mar 13;6:289-300. doi: 10.2147/IJWH.S49781. eCollection 2014.Int J Womens Health. 2014.PMID:24648773Free PMC article.Review.
• A Comprehensive Review of Mammalian Pigmentation: Paving the Way for Innovative Hair Colour-Changing Cosmetics.

  Fernandes B, Cavaco-Paulo A, Matamá T.Fernandes B, et al.Biology (Basel). 2023 Feb 11;12(2):290. doi: 10.3390/biology12020290.Biology (Basel). 2023.PMID:36829566Free PMC article.Review.
• Rapid hair depigmentation in patient treated with pazopanib.

  Šeparović R, Pavlović M, Silovski T, Tečić Vuger A.Šeparović R, et al.BMJ Case Rep. 2018 Aug 23;2018:bcr2018224209. doi: 10.1136/bcr-2018-224209.BMJ Case Rep. 2018.PMID:30139781Free PMC article.
• Hair disorders in patients with cancer.

  Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME.Freites-Martinez A, et al.J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14.J Am Acad Dermatol. 2019.PMID:29660422Free PMC article.Review.

Publication types

• Case Reports
• Research Support, N.I.H., Extramural

MeSH terms

• Adenoma, Oxyphilic / drug therapy
• Adult
• Black or African American
• Female
• Hair / drug effects
• Hair / pathology
• Humans
• Hypopigmentation / chemically induced*
• Indazoles
• Protein Kinase Inhibitors / adverse effects*
• Protein Kinase Inhibitors / therapeutic use
• Pyrimidines / adverse effects*
• Pyrimidines / therapeutic use
• Skin / drug effects
• Skin / pathology
• Sulfonamides / adverse effects*
• Sulfonamides / therapeutic use
• Thyroid Neoplasms / drug therapy

Substances

• Indazoles
• Protein Kinase Inhibitors
• Pyrimidines
• Sulfonamides
• pazopanib

Related information

• PubChem Compound
• PubChem Compound (MeSH Keyword)
• PubChem Substance

Grants and funding

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database